Sex differences in brain atrophy and cognitive impairment in Parkinson’s disease patients with and without probable rapid eye movement sleep behavior disorder

Javier Oltra1,2 · Barbara Segura1,2,3 · Carme Uribe1,2,4 · Gemma C. Monté-Rubio1 · Anna Campabadal1,2 · Anna Inguanzo1,2 · Jèssica Pardo1 · Maria J. Martí2,3,5 · Yaroslau Compta2,3,5 · Francesc Valldeoriola2,3,5 · Alex Iranzo2,3,6 · Carme Junque1,2,3

Received: 1 April 2021 / Revised: 20 July 2021 / Accepted: 25 July 2021
© The Author(s) 2021

Abstract

Background The presence of rapid eye movement sleep behavior disorder (RBD) contributes to increase cognitive impairment and brain atrophy in Parkinson’s disease (PD), but the impact of sex is unclear. We aimed to investigate sex differences in cognition and brain atrophy in PD patients with and without probable RBD (pRBD).

Methods Magnetic resonance imaging and cognition data were obtained for 274 participants from the Parkinson’s Progression Marker Initiative database: 79 PD with pRBD (PD-pRBD; male/female, 54/25), 126 PD without pRBD (PD-non pRBD; male/female, 73/53), and 69 healthy controls (male/female, 40/29). FreeSurfer was used to obtain volumetric and cortical thickness data.

Results Males showed greater global cortical and subcortical gray matter atrophy than females in the PD-pRBD group. Significant group-by-sex interactions were found in the pallidum. Structures showing a within-group sex effect in the deep gray matter differed, with significant volume reductions for males in one structure in in PD-non pRBD (brainstem), and three in PD-pRBD (caudate, pallidum and brainstem). Significant group-by-sex interactions were found in Montreal Cognitive Assessment (MoCA) and Symbol Digits Modalities Test (SDMT). Males performed worse than females in MoCA, phonemic fluency and SDMT in the PD-pRBD group.

Conclusion Male sex is related to increased cognitive impairment and subcortical atrophy in de novo PD-pRBD. Accordingly, we suggest that sex differences are relevant and should be considered in future clinical and translational research.

Keywords Parkinson’s disease · Sex differences · REM sleep behavior disorder · Magnetic resonance imaging · Gray matter atrophy · Cognitive impairment

Introduction

There is significant cumulative evidence for Alzheimer’s disease [1] and Parkinson’s disease (PD) [2, 3] that susceptibility to regional brain atrophy and cognitive impairment differs by sex. These between-sex differences on brain degeneration have implications for implementing prevention, diagnosis, and treatment strategies in the context of precision medicine.

Early population-based studies report that males have a two-fold increased risk of developing PD [4]. Males with PD, in comparison to females, also have decreased performance in global cognition [5–8], memory [6–8], verbal fluency [5, 7–9], processing speed [7, 9], and inhibition [9]. In contrast, females with PD have greater impairment in visuospatial function than males [6–8]. A recent meta-analysis revealed greater frontal executive deficit in males than females [10]. In addition, male sex is associated with cognitive impairment [11] and with progression to mild cognitive impairment (MCI) [8, 12] as well as dementia [12]. Male sex is an established predictor of progressive cognitive decline [13].

Structural magnetic resonance imaging (MRI) studies have also evidenced sex-based differences in PD. Males have
pronounced cortical thinning in frontal, parietal, temporal, and occipital regions compared with females [14]. Greater tissue loss in males with de novo PD has also been described in some cortical regions and in the left thalamus by deformation-based morphometry [15]. Studies have also identified disrupted structural connectivity in PD males compared to PD females [14, 15].

Isolated rapid eye movement behavior disorder (RBD) is a well-known prodrome of the synucleinopathies, with a rate of conversion of 90% after 15-year follow-up [16]. For unknown reasons, about 80% of the patients diagnosed in sleep centers with isolated RBD are of male sex [17]. PD patients have a prevalence of RBD symptomatology of around 40% [18]. The presence of probable RBD (pRBD) in PD has also been associated with more severe cognitive impairment in patients with de novo PD [19, 20], with a greater degree of cognitive decline over time [19]. Moreover a higher prevalence of MCI has been reported in PD patients with polysomnographic diagnosis of RBD [21]. Structural MRI studies in patients with de novo PD indicate that cortical [22] and subcortical volumes [22, 23] are reduced in groups with pRBD compared to groups without pRBD. To the best of our knowledge, no previous studies have investigated the impact of sex differences on brain atrophy and cognitive deficits in patients with PD and pRBD.

In the current work, we aimed to explore sex differences in brain and cognition in a large sample of newly diagnosed drug-naïve patients with PD, with and without probable RBD (PD-pRBD and PD-non pRBD groups, respectively). We hypothesized that the between-sex differences would be more marked in the PD-pRBD group than in the PD-non pRBD due to a greater degree of neurodegeneration.

**Methods**

**Participants**

Data were obtained from the Parkinson’s Progression Markers Initiative database (PPMI, http://www.ppmi-info.org) [24], including T1-weighted images, clinical information, and neuropsychological data from 205 patients with PD and 69 healthy controls. The PD cohort was then divided into four groups by their sex and pRBD status, the latter of which was established based on a five-point cutoff on the RBD Screening Questionnaire (RBDSQ) [25]. The final sample comprised 6 groups: 73 PD-non pRBD males, 53 PD-non pRBD females, 54 PD-pRBD males, 25 PD-pRBD females, 40 control males, and 29 control females.

The inclusion criteria were as follows: (i) recent diagnosis of PD with asymmetric resting tremor or asymmetric bradykinesia, or two from among bradykinesia, resting tremor, and rigidity; (ii) absence of PD treatment; (iii) neuroimaging evidence of significant dopamine transporter deficit consistent with a clinical diagnosis of PD, and excluding conditions that can mimic PD, such as drug-induced and vascular parkinsonism or essential tremor; (iv) T1-weighted images available (PD and control groups); and (v) age older than 50 and younger than 85 years old (PD and control groups).

The exclusion criteria for all participants were as follows: (i) diagnosis of dementia; (ii) significant psychiatric, neurological, or systemic comorbidity; (iii) a first-degree family member with PD; and (iv) presence of MRI motion artifacts, field distortions, intensity inhomogeneities, or detectable structural brain lesions. The sample selection process is shown in Supplementary Fig. 1.

**Clinical and neuropsychological assessments**

A detailed clinical assessment was performed. This included measurements of PD symptoms by the Movement Disorders Society Unified PD Rating Scale (MDS-UPDRS), PD motor symptoms by the MDS-UPDRS motor section (Part III), disease severity by the Hoehn and Yahr scale (H&Y), global cognition by the Montreal Cognitive Assessment (MoCA), depressive symptoms by the 15-item Geriatric Depression Scale (GDS-15), olfactory function by the University of Pennsylvania Smell Identification Test (UPSIT-40), probable RBD status and symptomatology by the RBDSQ, and excessive daytime sleepiness by the Epworth Sleepiness Scale (ESS) [24]. All subjects also underwent a neuropsychological battery that included the following: phonemic (letter ‘f’) and semantic (animals, fruits and vegetables) verbal fluency tests; the Symbol Digit Modalities Test (SDMT); Letter-Number Sequencing (LNS); the Benton Judgment of Line Orientation short form (JLO), 15-item version; and the Hopkins Verbal Learning Test-Revised (HVLT-R) [24]. All neuropsychological data were reported using z scores calculated based on the control group’s means and standard deviations.

**MRI images**

T1-weighted MRI scans were acquired using 1.5 or 3-Tesla scanners at different centers using magnetization prepared rapid gradient echo imaging (MPRAGE) sequences. Typical MRI parameters were as follows: repetition time = 5–11 ms; echo time = 2–6 ms; slice thickness 1–1.5 mm; inter-slice gap 0 mm; voxel size 1 × 1 × 1.2 mm; matrix 256 × 160 minimum. Details can be found at http://www.ppmi-info.org/wp-content/uploads/2010/07/Imaging-Manual.pdf. There were no differences in the distribution of 1.5 and 3-Tesla images across groups (Supplementary Table 1).

Cortical thickness was estimated using the automated processing stream and specific segmentation tools of FreeSurfer (version 6.0, http://surfer.nmr.mgh.harvard.edu). Uribe et al. provide a detailed description about processing...
Statistical analyses

The main effects of group and sex were computed for the demographic variables by two-way analysis of variance (ANOVA) followed by Bonferroni post hoc tests to analyze sex differences in group conditions. These analyses revealed that males were significantly older than females in the control group; consequently, subsequent analyses that involved this group included age as a covariate (Table 1). No significant main effect of group was found by age \( (F = 1.892, p = 0.153) \), education \( (F = 2.959, p = 0.054) \), age of disease onset \( (F = 3.264, p = 0.072) \), or PD duration \( (F = 0.045, p = 0.832) \). There were no differences in the sex distribution across the PD groups and healthy controls (Chi-squared = 2.558, \( p = 0.278 \)).

The group-by-sex interaction for clinical, neuropsychological, volumetric, and mean cortical thickness variables was assessed by two-way ANOVA or covariance (ANCOVA), followed by Bonferroni post hoc tests, as appropriate. Pearson’s Chi-squared test was used to analyze differences in categorical measures.

Additionally, we explored the within-group sex effect of neuropsychological, mean cortical thickness and volumetric variables. First, we regressed out the effect of normal aging and sex. Expected z scores adjusted for age and sex were calculated based on a multiple regression analysis performed in the HC group and subtracted from the observed variables [28]. Second, within-group sex effects and group-by-sex interactions were explored by two-way ANOVA followed by Bonferroni post hoc tests. Lastly, the between-group differences regarding the within-group sex effects were estimated to explore the significant group-by-sex interactions. The statistical significance threshold was set at \( p < 0.05 \) and all

### Table 1 Demographic and clinical characteristics of HC, PD-non pRBD, and PD-pRBD females and males

|                  | HC             | PD-non pRBD   | PD-pRBD  | Sex main effect test stat \( (P \) value) |
|------------------|----------------|---------------|----------|-----------------------------------------|
| Age, years       |                |               |          |                                         |
| F 60.6 (5.9)     | 60.9 (7.4)     | 63.5 (7.5)    | 6.215 (0.013)* |
| M 64.1 (7.1)     | 63.2 (7.4)     | 64.7 (7.0)    |          |                                         |
| Education, years |                |               |          |                                         |
| F 16.2 (2.9)     | 15.4 (2.9)     | 15.2 (3.1)    | 3.141 (0.077) |
| M 17.0 (2.5)     | 15.8 (3.0)     | 16.1 (2.9)    |          |                                         |
| Age of onset, years |          |               |          |                                         |
| F NA 60.0 (7.4)  | 62.6 (7.6)     | 2.348 (0.127) |          |                                         |
| M NA 62.3 (7.2)  | 63.6 (6.9)     |              |          |                                         |
| PD duration, months |            |               |          |                                         |
| F NA 10.8 (8.5)  | 9.9 (6.8)      | 0.278 (0.599) |          |                                         |
| M NA 10.3 (6.2)  | 11.6 (7.2)     |              |          |                                         |
| MDS-UPDRS        |                |               |          |                                         |
| F NA 28.4 (10.0) | 32.0 (11.9)    | 3.774 (0.053) |          |                                         |
| M NA 30.1 (11.3) | 37.4 (14.1)    |              |          |                                         |
| MDS-UPDRS Part III |            |               |          |                                         |
| F NA 19.0 (7.6)  | 17.9 (7.6)     | 7.371 (0.007)** |       |                                         |
| M NA 20.4 (8.3)  | 23.3 (9.4)     |              |          |                                         |
| H&Y stage, n, 1/2/3 |          |               |          |                                         |
| F NA 1.7 (2.1)   | 2.6 (2.5)      | 0.002 (0.967) |          |                                         |
| M NA 35/37/1     | 21/33/0        |              |          |                                         |
| GDS-15           |                |               |          |                                         |
| F 1.9 (3.2)      | 1.7 (2.1)      | 2.6 (2.5)     | 0.002 (0.967) |
| M 1.2 (2.8)      | 2.3 (2.2)      | 2.7 (2.4)     |          |                                         |
| ESS              |                |               |          |                                         |
| F 4.6 (2.9)      | 4.9 (3.4)      | 6.8 (3.6)     | 0.822 (0.365) |
| M 5.3 (3.5)      | 5.7 (2.9)      | 6.4 (3.7)     |          |                                         |
| RBDSQ            |                |               |          |                                         |
| F 1.5 (1.2)      | 2.7 (1.1)      | 6.0 (1.4)     | 7.405 (0.007)** |        |
| M 1.9 (1.4)      | 2.6 (1.1)      | 7.2 (1.9)     |          |                                         |
| UPSIT            |                |               |          |                                         |
| F 34.9 (3.4)     | 23.8 (8.6)     | 21.4 (8.7)    | 3.401 (0.066) |
| M 33.6 (4.1)     | 21.0 (7.4)     | 18.7 (8.0)    |          |                                         |

Data are presented by groups as mean (SD), except for H&Y. Two-way analyses of variance (ANOVA) followed by Bonferroni post hoc tests were used for all demographic variables. Two-way analyses of covariance (ANCOVA) with age as covariate, followed by Bonferroni post hoc tests were used for all clinical variables. Except for MDS-UPDRS, that was analyzed by two-way analysis of variance (ANOVA); and H&Y, by Pearson’s Chi-squared

ESS Epworth Sleepiness Scale; F female; GDS-15 the 15-item Geriatric Depression Scale; HC healthy controls; H&Y Hoehn and Yahr scale; M male; MDS-UPDRS Movement Disorder Society Unified Parkinson’s Disease Rating Scale; PD-non pRBD PD without probable RBD; PD-pRBD PD with probable RBD; RBDSQ REM Sleep Behavior Disorder Screening Questionnaire; UPSIT University of Pennsylvania Smell Identification Test

*Sex differences in HC group \( (P < 0.05) \)

**Sex differences in PD-pRBD group \( (P < 0.05) \)
analyses were performed with IBM SPSS Statistics 27.0.0 (2020; IBM Corp., Armonk, NY). Intergroup comparisons of cortical thickness were performed using a vertex-by-vertex general linear model in FreeSurfer v6.0. The model included cortical thickness as a dependent factor, group as an independent factor, and demeaned age as covariable. All results were corrected for multiple comparisons using a pre-cached cluster-wise Monte Carlo simulation with 10,000 iterations. Reported cortical regions reached a two-tailed corrected significance level of $p < 0.05$.

**Results**

**Clinical characteristics**

A significant sex effect was found with motor severity (MDS-UPDRS Part III) and RBD (RBDSQ). There was a significant group-by-sex interaction in the RBDSQ score ($F = 4.749, p = 0.009$), with post hoc analyses also showing that males in the PD-pRBD group had more severe motor and RBD symptoms than females in this group. No significant main effect of sex was found in the global MDS-UPDRS score, the H&Y stage, GDS-15, ESS, and UPSIT scores (Table 1).

**Neuropsychological performance**

A significant group-by-sex interaction was found in the MoCA ($F = 4.758, p = 0.009$) and SDMT ($F = 4.196, p = 0.016$). Both groups of PD males performed worse than HC males in MoCA and SDMT. PD-pRBD males performed worse than PD-non pRBD males in SDMT (Fig. 1 and Supplementary Table 3).

Complementary, significant within-group sex effects were found in the MoCA, phonemic fluency and SDMT in the PD-pRBD group after regressing out age and sex, in which males performed lower than females (Supplementary Table 4). A significant within-group sex effect in semantic fluency (fruits) was observed in the PD-non pRBD group, with lower performance in females than males. No within-group sex effect was observed in the control group. Significant group-by-sex interactions remained after controlling the effect of normal aging and sex (Supplementary Tables 4 and 5). Between-groups differences regarding the within-group sex effects in MoCA and SDMT showed significant differences between PD-pRBD and the other two groups (Supplementary Table 5).

**Fig. 1** Neuropsychological performance. Tasks are indicated in the $x$ axis. Group means in each task are presented as $z$ scores, as indicated in $y$ axis. Lower $z$ scores indicate worse performance. Descriptive statistics, as mean (SD), are available in Supplementary Table 3. Healthy controls in blue, PD-non pRBD in warm colors, PD-pRBD in green; lighter for females and darker for males. HC represented by filled squares, PD-non pRBD by filled triangles and PD-pRBD by filled rhombuses. Females by a continuous line and males by a dashed line. Data are presented as $z$ scores. Abbreviations: MoCA Montreal Cognitive Assessment; SDMT Symbol Digit Modalities Test; LNS Letter-Number Sequencing; JLO Benton Judgment of Line Orientation; HVLT-R Hopkins Verbal Learning Test-Revised, HC healthy controls; PD-non pRBD PD without probable RBD; PD-pRBD PD with probable RBD
MRI volumetry

We did not find any vertex-wise sex effects in cortical thickness. Regarding subcortical volumetry, there was a significant group-by-sex interaction in the bilateral pallidum ($F = 3.084, p = 0.047$). Post hoc analyses showed that PD-pRBD males had smaller pallidum volume than PD-non pRBD males (Table 2).

Supplementary analysis, after regressing out age and sex, showed that in the PD-pRBD group males had smaller global cortical and subcortical GM volumes than females. Furthermore, males had significantly smaller volume than females in three subcortical structures in the PD-pRBD group (caudate, pallidum and brainstem) versus in one in the PD-non pRBD group (brainstem), and in none in the control group (Supplementary Table 6). Significant group-by-sex interaction remained after controlling the effect of normal aging and sex (Supplementary Tables 5 and 6). Between-groups differences regarding the within-group sex effects showed a significant difference between PD groups and a trend to significance between PD-pRBD and HC in the pallidum. As expected, there were no differences between PD-non pRBD and HC (Supplementary Table 5).

Significant group-by-sex interactions in neuropsychological (MoCA) and MRI (pallidum) measures remain significant after controlling by motor disease severity (Supplementary Tables 7 and 8).

In summary, we showed a significant interaction in pallidum, showing smaller pallidum volume in PD-pRBD males than in PD-non pRBD males. Additionally, PD-pRBD males showed smaller global cortical and subcortical GM volumes than females, as well as, a different number of structures showing within-group sex differences. This applied to no structure in the control group, one in the PD-non pRBD group, and three in the PD-pRBD group. In all cases, males showed decreased volumes compared with females.

Discussion

Among drug-naïve patients, in the PD-pRBD group males had more severe motor and RBD symptomatology, worse cognitive performance, and greater subcortical volume atrophy than females. Such sex differences were also observed in subcortical volumes in PD-non pRBD group, but to a greater extent in the former.

Clinically, despite a similar age at the time of the study, age of disease onset and PD duration, males in the PD-pRBD group had greater motor impairment and more RBD symptoms. Cognitive impairment was also greater in males in the PD-pRBD group. We found a significant group-by-sex interaction in MoCA and SDMT. Notably, the sex effects in MoCA and SDMT were greater in the PD-pRBD group compared with the other two groups. Specifically, we found that males performed significantly worse than females in

| Table 2 Magnetic resonance imaging derived measures of HC, PD-non pRBD, and PD-pRBD females and males |
|---------------------------------------------------------------|
| **HC** | **PD-non pRBD** | **PD-pRBD** | **Group-by-sex test stat ($P$ value)** |
| **Global atrophy** | | | |
| Cortical GM | | | |
| F | 30.11 (1.80) | 29.39 (2.23) | 30.03 (2.34) | 1.577 (0.209) |
| M | 29.39 (2.26) | 28.15 (1.98) | 28.15 (2.39) | |
| Subcortical GM | | | |
| F | 3.69 (0.27) | 3.63 (0.26) | 3.66 (0.32) | 1.773 (0.172) |
| M | 3.54 (0.28) | 3.51 (0.24) | 3.41 (0.24) | |
| Mean CTh, mm | | | |
| F | 2.44 (0.10) | 2.42 (0.10) | 2.41 (0.09) | 0.017 (0.984) |
| M | 2.41 (0.12) | 2.39 (0.12) | 2.38 (0.12) | |
| **Deep GM nuclei** | | | |
| Thalamus | | | |
| F | 0.460 (0.030) | 0.465 (0.042) | 0.456 (0.044) | 0.741 (0.478) |
| M | 0.443 (0.046) | 0.441 (0.040) | 0.429 (0.037) | |
| Caudate | | | |
| F | 0.222 (0.028) | 0.221 (0.027) | 0.229 (0.022) | 2.047 (0.131) |
| M | 0.215 (0.024) | 0.212 (0.025) | 0.207 (0.024) | |
| Putamen | | | |
| F | 0.303 (0.038) | 0.294 (0.035) | 0.296 (0.039) | 0.995 (0.371) |
| M | 0.290 (0.034) | 0.286 (0.029) | 0.275 (0.035) | |
| Pallidum | | | |
| F | 0.126 (0.013) | 0.127 (0.014) | 0.131 (0.015) | 3.084 (0.047)* |
| M | 0.124 (0.015) | 0.127 (0.013) | 0.120 (0.015) | |
| Hippocampus | | | |
| F | 0.279 (0.028) | 0.267 (0.030) | 0.272 (0.031) | 0.802 (0.449) |
| M | 0.257 (0.026) | 0.252 (0.028) | 0.247 (0.025) | |
| Amygdala | | | |
| F | 0.110 (0.013) | 0.103 (0.015) | 0.108 (0.022) | 2.397 (0.093) |
| M | 0.110 (0.014) | 0.105 (0.013) | 0.101 (0.013) | |
| Accumbens | | | |
| F | 0.032 (0.006) | 0.031 (0.007) | 0.034 (0.007) | 1.618 (0.200) |
| M | 0.031 (0.004) | 0.030 (0.006) | 0.030 (0.006) | |
| Brainstem | | | |
| F | 1.382 (1.00) | 1.412 (1.128) | 1.412 (1.10) | 2.393 (0.093) |
| M | 1.390 (1.134) | 1.375 (0.113) | 1.338 (0.128) | |

Data are presented by groups as mean (SD). Volumetric variables are presented in ratios estimated by ((volume/eTIV) × 100). Two-way analyses of covariance (ANCOVA) with age as covariable, followed by Bonferroni post hoc tests, were used for all variables CTh cortical thickness; F female; GM gray matter; HC healthy controls; M male; PD-non pRBD PD without probable RBD; PD-pRBD PD with probable RBD

* Differences between PD-non pRBD males and PD-pRBD males ($P < 0.05$)
expression and sex hormones have been related to these sex differences in neurodegenerative processes. Dysregulated gene have been suggested as being responsible for sex differ-
neurodegeneration. Several pathophysiological mechanisms of sex differences in cognition and brain structure follow -
ce, in the brainstem.

but the PD-non pRBD group showed only one sex differ -
ences in the bilateral pallidum, caudate, and brainstem; ap-
plied classification, the PD-pRBD group showed sex dif-
thalamus compared to females [15]. However, following the
PD as a whole group, using voxel-based morphometry,
group and none structure in the control group. In de novo
compared with only one structures in the PD-non pRBD
cant differences in three structures in the PD-pRBD group
with the PD-non pRBD group. Specifically, we found signifi-
causal structures. There was increased subcortical atrophy in
compared with females, we also found vulnerability to dif-
several genes involved in the regulation of neuronal
apoptosis, inflammation/immunity, and susceptibility to neu-
rological disorders have been identified [34]. Nevertheless,
in the future, other functional biomarkers and imaging tech-
niques are needed to investigate the specific mechanisms
underlying sex-related brain differences in PD.

The main strength of the paper is a very large sample that
allows testing sex effects on brain and cognition in PD and
the main limitation of our study is using a validated RBD
questionnaire instead of a confirmed polysomnography diag-
nosis. In this sense, the RBDSQ showed a sensitivity of 0.47
and a specificity of 0.78 in a cohort of PD de novo patients
[35]. The use of a questionnaire could increment the false
positive discovery rate by overestimating the incidence of
clinically significant RBD symptomatology and limit the
generalisability of the obtained results. Another limitation
is that PPMI data were acquired from a multicenter cohort
having differences in MRI acquisition. Finally, we could not
have a group of healthy controls with probable RBD to take
into account the influence of this condition isolated.

In summary, our results underpin the role of sex as being
important to understanding the phenotypic expression of
PD. Our findings also indicate that sex male is related to
increased functional alterations in motor, RBD, and cogni-
tive domains among drug-naïve PD patients with pRBD.
Also, PD-pRBD male patients show more atrophy in subcor-
tical structures than PD-pRBD females and these sex differ-
ences are in more structures than in patients without pRBD.
Accordingly, we suggest that sex differences are relevant
factors to be considered in clinical trials.

Supplementary Information The online version contains supplemen-
tary material available at https://doi.org/10.1007/s00415-021-10728-x.

Acknowledgements Parkinson’s Progression Marker Initiative
(PPMI)—a public–private partnership—is funded by the Michael
J. Fox Foundation for Parkinson’s Research and funding partners,
including Abbvie, Acurex Therapeutics, Allergan, Amathus Thera-
peutics, Aligning Science Across Parkinson’s, Avid Radiophar-
maeuticals, Bial Biotech, Biogen, BioLegend, Bristol Myers Squibb,
Calico, Celgene, Dacapo Brainscience, Denali, 4D Pharma Pec., F.
Dmond J. Safram Philanthropic Foundation, GE Healthcare, Genen-
tec, GlaxoSmithKline, Golub Capital, Handl Therapeutics, Insitro,
Janssen Neuroscience, Lilly, Lundbeck, Merck. Meso Scale Discov-
ery, Neurocrine Biosciences, Pfizer, Piramal, Prevail Therapeutics,
Roche, Sanofi Genzyme, Servier, Takeda, Teva, Ucb, Verily and
Voyager Therapeutics. We acknowledge the Centres de Recerca de

MoCA, phonemic fluency and SDMT in the PD-pRBD
group. By contrast, females in the PD-non pRBD showed
greater impairment only in one semantic fluency test than males. These results suggest that, if PD patients with RBD
symptomatology, showed sex differences consistent with
those of previous studies in drug-naïve patients with PD
as a whole group, showing that males have greater global
cognitive impairment [6, 7], verbal fluency, and processing
speed [7] impairments. In contrast, those differences mostly
disappear, in the PD-non pRBD group.

Global MRI measures revealed smaller total cortical and
subcortical GM volumes in males of the PD-pRBD group,
but not in the PD-non pRBD and control groups. This find-
ing suggesting that, just like the atrophy patterns are more
severe in PD with RBD symptomatology [22, 23], the sex
differences are more marked in this PD subtype.

It has been reported that males, even adjusting for brain
size, have larger volumes in several structures than females
[29, 30]. Nonetheless, more accelerated aging effects have
been described in males in regional volumes [31, 32]. In
summary, aging seems to reverse sex-related structural
differences in the brain, probably due to hormonal effects,
resulting in a greater vulnerability of males to brain atrophy,
especially in degenerative conditions.

In addition to the greater global atrophy among males
compared with females, we also found vulnerability to dif-
ferential volumetric atrophy by sex among various subcor-
tical structures. There was increased subcortical atrophy in
males compared with females in both PD groups, and we
observed that sex differences in subcortical regions were
more evident in the PD-pRBD group, with a significant
group-by-sex interaction in the pallidum. The sex effect in
the pallidum was greater in the PD-pRBD group compared
with the PD-non pRBD group. Specifically, we found signific-
ificant differences in three structures in the PD-pRBD group
compared with only one structures in the PD-non pRBD
group and none structure in the control group. In de novo
PD as a whole group, using voxel-based morphometry,
males have been shown to have increased atrophy in the left
thalamus compared to females [15]. However, following the
applied classification, the PD-pRBD group showed sex dif-
fferences in the bilateral pallidum, caudate, and brainstem;
but the PD-non pRBD group showed only one sex differ-
ence, in the brainstem.

Together, our results provide evidence for the presence
of sex differences in cognition and brain structure follow-
ing a continuum from normal aging to patients with PD and
pRBD. In both PD groups, males show more severe atrophy,
suggesting that female sex confers protective benefits against
neurodegeneration. Several pathophysiological mechanisms
have been suggested as being responsible for sex differ-
ences in neurodegenerative processes. Dysregulated gene
expression and sex hormones have been related to these sex
differences in the pathophysiology of PD, including vulner-
ability of the dopaminergic system, neuroinflammation, and
oxidative stress [2]. Another implicated mechanism is the
alpha-synuclein, that has been observed in more decreased
plasma concentrations in males than females in advanced
stages of PD; and its concentration has been associated with
cognitive impairment and sleep disorders in PD males [33].
By analyzing the subcortical structural volumes of 38,851
subjects, several genes involved in the regulation of neuronal
apoptosis, inflammation/immunity, and susceptibility to neu-
rological disorders have been identified [34]. Nevertheless,
in the future, other functional biomarkers and imaging tech-
niques are needed to investigate the specific mechanisms
underlying sex-related brain differences in PD.

In summary, our results underpin the role of sex as being
important to understanding the phenotypic expression of
PD. Our findings also indicate that sex male is related to
increased functional alterations in motor, RBD, and cogni-
tive domains among drug-naïve PD patients with pRBD.
Also, PD-pRBD male patients show more atrophy in subcor-
tical structures than PD-pRBD females and these sex differ-
ences are in more structures than in patients without pRBD.
Accordingly, we suggest that sex differences are relevant
factors to be considered in clinical trials.

Supplementary Information The online version contains supplemen-
tary material available at https://doi.org/10.1007/s00415-021-10728-x.

Acknowledgements Parkinson’s Progression Marker Initiative
(PPMI)—a public–private partnership—is funded by the Michael
J. Fox Foundation for Parkinson’s Research and funding partners,
including Abbvie, Acurex Therapeutics, Allergan, Amathus Thera-
peutics, Aligning Science Across Parkinson’s, Avid Radiophar-
maeuticals, Bial Biotech, Biogen, BioLegend, Bristol Myers Squibb,
Calico, Celgene, Dacapo Brainscience, Denali, 4D Pharma Pec., F.
Dmond J. Safram Philanthropic Foundation, GE Healthcare, Genen-
tec, GlaxoSmithKline, Golub Capital, Handl Therapeutics, Insitro,
Janssen Neuroscience, Lilly, Lundbeck, Merck. Meso Scale Discov-
ery, Neurocrine Biosciences, Pfizer, Piramal, Prevail Therapeutics,
Roche, Sanofi Genzyme, Servier, Takeda, Teva, Ucb, Verily and
Voyager Therapeutics. We acknowledge the Centres de Recerca de

@Springer
Catalunya (CERCA) Programme/Generalitat de Catalunya, the Institute of Neurosciences, and the Institute of Biomedical Research August Pi i Sunyer (IDIBAPS).

Author contributions Research project conception and acquisition of data are explained in Marek et al. 2011 as cited in the text. CJ and BS contributed to the design of the study. JO, BS, CU, GM and CJ contributed to the analysis of the data and JO, BS, CU, CM, AC, Alguanzo, JP and CJ contributed to the interpretation of the data. JO, BS, CU, and CJ contributed to the draft of the article. JO, BS, CU, MJM, YC, FV, Arazno and CJ revised the manuscript critically for important intellectual content and approved the final version of the manuscript.

Funding This study was sponsored by the Spanish Ministry of Economy and Competitiveness (PSI2017-86930-P) cofinanced by Agencia Estatal de Investigación (AEI) and the European Regional Development Fund (ERDF), by Generalitat de Catalunya (2017SGR748), and supported by María de Maeztu Unit of Excellence (Institute of Neurosciences, University of Barcelona) MDM-2017-0729, Ministry of Science, Innovation and Universities. JO was supported by a 2018 fellowship from the Spanish Ministry of Science, Universities and Research and cofinanced by the European Social Fund (PRE2018-086675). CU was supported by the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie fellowship (Grant Agreement 88692). Alguanzo was supported by APIF predoctoral fellowship from the University of Barcelona (2017–2018). YC has received funding in the past 5 years from FIS/FEDER, H2020 programme.

Data availability Data used in the preparation of this article were obtained from the Parkinson’s Progression Markers Initiative (PPMI) database (www.ppmi-info.org/data). For up-to-date information on the database (www.ppmi-info.org/data). For up-to-date information on the study, visit www.ppmi-info.org.

Code availability Not applicable.

Declarations

Conflicts of interest MJM received honoraria for advice and lecture from Abbvie, Bial and Merz&Pharma and grants from Michael J. Fox Foundation for Parkinson’s Research (MJFF): MJF_PPMI_10_001, PI044024. YC has received funding in the past 5 years from Union Chimique Belge (UCB pharma), Teva, Medtronic, Abbvie, Novartis, Merz, Piramal Imaging, and Esteve, Bial, and Zambon. YC is currently an associate editor for Parkinsonism & Related Disorders.

Ethical approval All participating PPMI sites received approval from an ethical standards committee prior to study initiation.

Consent to participate and consent to publication All participating PPMI sites obtained written informed consent for research from all participants in the study as described in the PPMI study protocol, available in https://www.ppmi-info.org/study-design/research-documents-and-sops/.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Ferretti MT, Iulita MF, Cavedo E et al (2018) Sex differences in Alzheimer disease—-the gateway to precision medicine. Nat Rev Neurol 14:457–469. https://doi.org/10.1038/nrneurol.2018.0032
2. Cerri S, Mus L, Blandini F (2019) Parkinson’s disease in women and men: what’s the difference? J Parkinsons Dis 9:501–515. https://doi.org/10.3233/JPD-191683
3. Turcano P, Savica R (2020) Sex differences in movement disorders, 1st edn. Elsevier B.V
4. Baldereschi M, Di Carlo A, Rocca WA et al (2000) Parkinson’s disease and Parkinsonism in a longitudinal study: two-fold higher incidence in men. Neurology 55:1358–1363. https://doi.org/10.1212/WNL.55.9.1358
5. Szewczyk-Krolkowski K, Tomlinson P, Nithi K et al (2014) The influence of age and gender on motor and non-motor features of early Parkinson’s disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. Parkinsonism Relat Disord 20:99–105. https://doi.org/10.1016/j.parkreldis.2013.09.025
6. Liu R, Umbach DM, Peddada SD et al (2015) Potential sex differences in nonmotor symptoms in early drug-naïve Parkinson disease. Neurology 84:2107–2115. https://doi.org/10.1212/WNL.000000000001609
7. Lin SJ, Baumeister TR, Garg S, McKeown MJ (2018) Cognitive profiles and hub vulnerability in Parkinson’s disease. Front Neurol 9:1–13. https://doi.org/10.3389/fneur.2018.00482
8. Bakeberg MC, Gorecki AM, Kenna JE et al (2021) Differential effects of sex on longitudinal patterns of cognitive decline in Parkinson’s disease. J Neurol. https://doi.org/10.1007/s00415-020-10367-8
9. Reekes TH, Higginson CI, Ledbetter CR et al (2020) Sex specific cognitive differences in Parkinson disease. NPJ Parkinsons Dis 6:1–6. https://doi.org/10.1038/s41531-020-0109-1
10. Curtis AF, Masellis M, Camicioli R et al (2019) Cognitive profile of non-demented Parkinson’s disease: meta-analysis of domain and sex-specific deficits. Parkinsonism Relat Disord 60:32–42. https://doi.org/10.1016/j.parkreldis.2018.10.014
11. Iwaki H, Blauwendraat C, Leonard HL et al (2021) Differences in the presentation and progression of Parkinson’s disease by sex. Mov Disord 36:106–117. https://doi.org/10.1002/mds.28312
12. Cholerton B, Johnson CO, Fish B et al (2018) Sex differences in progression to mild cognitive impairment and dementia in Parkinson’s disease. Parkinsonism Relat Disord 50:29–36. https://doi.org/10.1016/j.parkreldis.2018.02.007
13. Liu G, Locascio JJ, Corvol JC et al (2017) Prediction of cognition in Parkinson’s disease with a clinical–genetic score: a longitudinal analysis of nine cohorts. Lancet Neurol 16:620–629. https://doi.org/10.1016/S1474-4422(17)30122-9
14. Yadav SK, Kathiresan N, Mohan S et al (2016) Gender-based analysis of cortical thickness and structural connectivity in Parkinson’s disease. J Neurol 263:2308–2318. https://doi.org/10.1007/s00415-016-8265-2
15. Tremblay C, Abbasi N, Zeighami Y et al (2020) Sex effects on brain structure in de novo Parkinson’s disease: a multimodal neuroimaging study. Brain 143:3052–3066. https://doi.org/10.1093/brain/awaa234
16. Galbiati A, Verga L, Giora E et al (2019) The risk of neurodegeneration in REM sleep behavior disorder: a systematic review and
17. Fernández-Arcos A, Iranzo A, Serradell M et al (2016) The clinical phenotype of idiopathic rapid eye movement sleep behavior disorder at presentation: a study in 203 consecutive patients. Sleep 39:121–132. https://doi.org/10.5665/sleep.5332

18. Zhang J, Xu CY, Liu J (2017) Meta-analysis on the prevalence of REM sleep behavior disorder symptoms in Parkinson’s disease. BMC Neurol 17:23. https://doi.org/10.1186/s12883-017-0795-4

19. Chahine LM, Xie SX, Simuni T et al (2016) Longitudinal changes in cognition in early Parkinson’s disease patients with REM sleep behavior disorder. Parkinsonism Relat Disord 27:102–106. https://doi.org/10.1016/j.parkreldis.2016.03.006

20. Trout J, Christiansen T, Bullkey MB et al (2020) Cognitive impairments and self-reported sleep in early-stage Parkinson’s disease with versus without probable REM sleep behavior disorder. Brain Sci. https://doi.org/10.3390/brainsci10010009

21. Jozwiak N, Postuma RB, Montplaisir J et al (2017) Rem sleep behavior disorder and cognitive impairment in Parkinson’s disease. Sleep. https://doi.org/10.1093/sleep/zsx101

22. Boucetta S, Salimi A, Dadar M et al (2016) Structural brain alterations associated with rapid eye movement sleep disorder in Parkinson’s disease. Sci Rep 6:26782. https://doi.org/10.1038/srep26782

23. Kamps S, van den Heuvel OA, van der Werf YD et al (2019) Smaller subcortical volume in Parkinson patients with rapid eye movement sleep behavior disorder. Brain Imaging Behav 13:1352–1360. https://doi.org/10.1007/s11682-018-9939-4

24. Marek K, Jennings D, Lasch S et al (2011) The Parkinson progression marker initiative (PPMI). Prog Neurobiol 95:629–635. https://doi.org/10.1016/j.pneurobiol.2011.09.005

25. Stiasny-Kolster K, Mayer G, Schäfer S et al (2007) The REM sleep behavior disorder screening questionnaire—a new diagnostic instrument. Mov Disord 22:2386–2393. https://doi.org/10.1002/mds.21740

26. Uribe C, Puig-Davi A, Abos A et al (2019) Neuroanatomical and functional correlates of cognitive and affective empathy in young healthy adults. Front Behav Neurosci 13:85

27. Fischl B, Salat DH, Busa E et al (2002) Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 33:341–355. https://doi.org/10.1016/S0896-6273(02)00569-X

28. Aarsland D, Bronnick K, Larsen JP et al (2009) Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest Study. Neurology 72:1121–1126. https://doi.org/10.1212/01.wnl.0000338632.00552.cb

29. Ritchie SJ, Cox SR, Shen X et al (2018) Sex differences in the adult human brain: evidence from 5216 UK biobank participants. Cereb Cortex 28:2959–2975. https://doi.org/10.1093/cercor/bhy109

30. Lotze M, Domin M, Gerlach FH et al (2019) Novel findings from 2838 adult brains on sex differences in gray matter brain volume. Sci Rep 9:1–7. https://doi.org/10.1038/s41598-018-38239-2

31. Király A, Szabó N, Tóth E et al (2016) Male brain ages faster: the age and gender dependence of subcortical volumes. Brain Imaging Behav 10:901–910. https://doi.org/10.1007/s11682-015-9468-3

32. Wang Y, Xu Q, Luo J et al (2019) Effects of age and sex on subcortical volumes. Front Aging Neurosci 11:1–12. https://doi.org/10.3389/fnagi.2019.00259

33. Caranci G, Piscopo P, Rivabene R et al (2013) Gender differences in Parkinson’s disease: focus on plasma alpha-synuclein. J Neural Transm 120:1209–1215. https://doi.org/10.1007/s00702-013-0972-6

34. Satizabal CL, Adams HHH, Hiba DP et al (2019) Genetic architecture of subcortical brain structures in 38,851 individuals. Nat Genet 51:1624–1636. https://doi.org/10.1038/s41588-018-0511-y

35. Halsband C, Zapf A, Sixel-Döring F et al (2018) The REM sleep behavior disorder screening questionnaire is not valid in de novo Parkinson’s disease. Mov Disord Clin Pract 5:171–176. https://doi.org/10.1002/mdc3.12591

Authors and Affiliations

Javier Oltra1,2 · Barbara Segura1,2,3 · Carme Uribe1,2,4 · Gemma C. Monté-Rubio1 · Anna Campabadal1,2 · Anna Inguanzo1,2 · Jéssica Pardo1 · Maria J. Marti2,3,5 · Yaroslau Compta2,3,5 · Francesc Valldeoriola2,3,5 · Alex Iranzo2,3,6 · Carme Junque1,2,3

Javier Oltra
joltra@ub.edu
Carme Uribe
carme.uribe@ub.edu
Gemma C. Monté-Rubio
gmonte@ub.edu
Anna Campabadal
anna.campabadal@ub.edu
Anna Inguanzo
anninguanzo@ub.edu
Jéssica Pardo
jpardoru@ub.edu
Maria J. Marti
mjmarti@clinic.cat
Yaroslau Compta
ycompta@clinic.cat
Francesc Valldeoriola
fvalde@clinic.cat
Alex Iranzo
airanzo@clinic.cat
Carme Junque
cjuanke@ub.edu

1 Medical Psychology Unit, Department of Medicine, Institute of Neurosciences, University of Barcelona, Barcelona, Spain
2 Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain
3 Centre de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII), Barcelona, Catalonia, Spain
4 Research Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), University of Toronto, Toronto, Canada
5 Parkinson’s Disease and Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institute of Neurosciences, University of Barcelona, Barcelona, Catalonia, Spain

6 Sleep Disorders Center, Neurology Service, Hospital Clínic, Barcelona, Catalonia, Spain